TICKERNERD
Menu
RZLTRZLTHealthcare · Biotechnology

RZLT Stock Forecast: Rezolute, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$4.64
+5.94% on the day

The 10 Wall Street analysts covering Rezolute, Inc. hold a median 12-month price target of $10 — +115.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$423.6M
Ticker Nerd rank
37 / 100
Median analyst target
$10
Analysts covering
10
Revenue$0.0
Operating income−$17.4M
Net income−$16.2M
Free cash flow−$13.7M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+14.0%
1M
+5.5%
YTD
+96.6%
1Y
−46.8%
From 52W high
−57.6%
From 52W low
+231.4%
$1
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RZLT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rezolute, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
77
Value
60
Size
54
Growth
49
Volatility
48
Issuance
45
Quality
39
Revisions
30
Momentum
28

Accruals (77): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (28): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RZLT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RZLT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26RZLTHigh $15Median $10Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $6Median $10High $15

The green dot is the last close — the median target sits +115.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Oct 2026Cantor FitzgeraldUpgradeOverweight—
6 Oct 2026CitizensMaintainsMarket Outperform$11 → $15
6 Oct 2026Lake StreetMaintainsBuy$9.00 → $12
30 Sept 2026Lake StreetInitiatesBuy$9.00
29 Sept 2026Craig-HallumUpgradeBuy$4.00 → $7.00
25 Sept 2026HC Wainwright & Co.MaintainsBuy$5.00 → $10
15 June 2026GuggenheimMaintainsBuy$6.00 → $11
15 June 2026GuggenheimMaintainsBuy—
3 June 2026CitizensUpgradeMarket Outperform—
3 June 2026Maxim GroupMaintainsBuy—
3 June 2026WedbushMaintainsOutperform—
2 June 2026BTIGMaintainsBuy—
2 June 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026Maxim GroupMaintainsBuy—
25 Mar 2026WedbushUpgradeOutperform—
8 Jan 2026BTIGReiteratesBuy—
8 Jan 2026WedbushMaintainsNeutral—
12 Dec 2025GuggenheimMaintainsBuy—
12 Dec 2025HC Wainwright & Co.MaintainsBuy—
20 Nov 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RZLT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RZLT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Rezolute, Inc. returned −46.8% against +16.2% for the S&P 500, dividends included.

RZLT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26RZLTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RZLT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Rezolute, Inc. (RZLT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.6×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
4.0×

Cheaper than 25% of US stocks

EV / EBITDA
−3.8×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.0%

Higher than 19% of US stocks

Return on assets
−35.3%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rezolute, Inc. (RZLT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rezolute, Inc. has a market value of $423.6M and an enterprise value of $311.0M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$81.5M.

  • Diluted earnings per share, trailing twelve months: $−0.82.

  • Free cash flow in the twelve months to 31 Mar 2026: −$73.5M.

  • Shares outstanding: 96.3M.

  • Trailing P/E: −4.6×; forward P/E: −9.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Rezolute, Inc. employs 58 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

RZLT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RZLTRezolute, Inc.$423.6M
37
SPRYARS Pharmaceuticals, Inc.$450.7M
12
OVIDOvid Therapeutics, Inc.$436.7M
64
ASMBAssembly Biosciences, Inc.$452.2M
88
EDITEditas Medicine, Inc.$435.8M
80
ENTXEntera Bio Ltd.$432.9M
44
DMACDiaMedica Therapeutics, Inc.$431.9M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rezolute, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RZLT news & analysis

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

GlobeNewsWire · 5 Oct 2026positive

Rezolute announced that the FDA has recommended holding a pre-BLA meeting, a precursor to submitting a Biologics License Application for the treatment of congenital hyperinsulinism. The Agency reiterated its commitment to addressing the unmet need in congenital and tumor-related hyperinsulinism and to serving those patient communities.

Why it matters — This signals regulatory progress toward a potential BLA submission for RZLT's congenital hyperinsulinism program.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update

GlobeNewsWire · 24 Sept 2026neutral

Rezolute, Inc. reported its financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. The company focuses on treating refractory hypoglycemia caused by any form of hyperinsulinism.

Why it matters — RZLT watchers would care because these fiscal year-end financial results and business update offer insight into the company's progress and financial standing as a late-stage rare disease developer.

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

GlobeNewsWire · 9 Sept 2026positive

Rezolute provided an update on the ongoing FDA review of its Phase 3 sunRIZE study data for ersodetug in congenital hyperinsulinism. The study's open-label extension phase continues with high participation and improved glycemic control indicators, while enrollment progresses in the Phase 3 upLIFT study with topline results expected before the end of 2026.

Why it matters — RZLT watchers would care because it offers an update on the FDA review timeline and encouraging early signs from the ongoing extension phase of the company's key Phase 3 program, as well as clarity on the upcoming upLIFT study results.

Rezolute to Participate in Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Rezolute, Inc., a late-stage ultra-rare disease company developing treatments for refractory hypoglycemia caused by hyperinsulinism, announced that its management will participate in upcoming investor conferences. The announcement was made via GlobeNewsWire on September 2, 2026.

Why it matters — RZLT watchers would care because management's participation in investor conferences provides opportunities for the company to communicate its progress and strategy directly to the investment community.

FAQ

Frequently asked questions about RZLT stock

What is the RZLT stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Rezolute, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RZLT stock a buy right now?

Of the 10 analysts covering Rezolute, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rezolute, Inc. 37 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RZLT?

As at 8 Oct 2026, Rezolute, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (77 of 100).

Will RZLT stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +115.5% from the last close, and Ticker Nerd's factor model ranks Rezolute, Inc. 37 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RZLT stock forecast for 2030?

No analyst covering Rezolute, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RZLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $15 over the next 12 months.

How has RZLT stock performed over the past year?

Rezolute, Inc. returned -46.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rezolute, Inc. do?

Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance.

What is the latest news on RZLT?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism". Rezolute announced that the FDA has recommended holding a pre-BLA meeting, a precursor to submitting a Biologics License Application for the treatment of congenital hyperinsulinism. The Agency reiterated its commitment to addressing the unmet need in congenital and tumor-related hyperinsulinism and to serving those patient communities.

Company

About Rezolute, Inc.

Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclonal antibody being studied for congenital hyperinsulinism and other forms of hypoglycemia caused by hyperinsulinism. The company’s pipeline also includes additional candidates aimed at conditions such as diabetic macular edema, reflecting a broader focus on endocrine and metabolic disorders. Rezolute Inc. works at the intersection of rare disease research and targeted drug development, with its programs designed to address serious conditions that have limited treatment options. Based in Redwood City, California, the company plays a specialized role in the biopharmaceutical market by advancing therapies for ultra-rare pediatric and metabolic diseases.

CEO Mr. Nevan Charles Elam J.D. · 58 employees · United States · https://www.rezolutebio.com